Your browser doesn't support javascript.
loading
Structure-based identification of inhibitors targeting obstruction of the HIVgp41 N-heptad repeat trimer.
McGee, T Dwight; Yi, Hyun Ah; Allen, William J; Jacobs, Amy; Rizzo, Robert C.
Afiliação
  • McGee TD; Department of Applied Mathematics & Statistics, Stony Brook University, Stony Brook, NY 11794, United States.
  • Yi HA; Department of Microbiology and Immunology, State University of New York at Buffalo, Buffalo, NY 14214, United States.
  • Allen WJ; Department of Applied Mathematics & Statistics, Stony Brook University, Stony Brook, NY 11794, United States.
  • Jacobs A; Department of Microbiology and Immunology, State University of New York at Buffalo, Buffalo, NY 14214, United States.
  • Rizzo RC; Department of Applied Mathematics & Statistics, Stony Brook University, Stony Brook, NY 11794, United States; Institute of Chemical Biology & Drug Discovery, Stony Brook University, Stony Brook, NY 11794, United States; Laufer Center for Physical & Quantitative Biology, Stony Brook Unive
Bioorg Med Chem Lett ; 27(14): 3177-3184, 2017 07 15.
Article em En | MEDLINE | ID: mdl-28558972
ABSTRACT
The viral protein HIVgp41 is an attractive and validated drug target that proceeds through a sequence of conformational changes crucial for membrane fusion, which facilitates viral entry. Prior work has identified inhibitors that interfere with the formation of a required six-helix bundle, composed of trimeric C-heptad (CHR) and N-heptad (NHR) repeat elements, through blocking association of an outer CHR helix or obstructing formation of the inner NHR trimer itself. In this work, we employed similarity-based scoring to identify and experimentally characterize 113 compounds, related to 2 small-molecule inhibitors recently reported by Allen et al. (Bioorg. Med. Chem Lett.2015, 25 2853-59), proposed to act via the NHR trimer obstruction mechanism. The compounds were first tested in an HIV cell-cell fusion assay with the most promising evaluated in a second, more biologically relevant viral entry assay. Of the candidates, compound #11 emerged as the most promising hit (IC50=37.81µM), as a result of exhibiting activity in both assays with low cytotoxicity, as was similarly seen with the known control peptide inhibitor C34. The compound also showed no inhibition of VSV-G pseudotyped HIV entry compared to a control inhibitor suggesting it was specific for HIVgp41. Molecular dynamics simulations showed the predicted DOCK pose of #11 interacts with HIVgp41 in an energetic fashion (per-residue footprints) similar to the four native NHR residues (IQLT) which candidate inhibitors were intended to mimic.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Desenho de Fármacos / Proteína gp41 do Envelope de HIV / HIV / Inibidores da Fusão de HIV Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Bioorg Med Chem Lett Assunto da revista: BIOQUIMICA / QUIMICA Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Desenho de Fármacos / Proteína gp41 do Envelope de HIV / HIV / Inibidores da Fusão de HIV Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Bioorg Med Chem Lett Assunto da revista: BIOQUIMICA / QUIMICA Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos